

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2025
(THE FIGURES HAVE NOT BEEN AUDITED)
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 MARCH 2025

	Note	3 MONTHS ENDED		PERIOD ENDED	
		31/3/2025	31/3/2024	31/3/2025	31/3/2024
		RM'000	RM'000	RM'000	RM'000
Revenue		238,870	248,178	238,870	248,178
Cost of sales		(183,302)	(192,413)	(183,302)	(192,413)
Gross profit		55,568	55,765	55,568	55,765
Other income		3,068	6,021	3,068	6,021
Selling & marketing expenses		(25,571)	(26,563)	(25,571)	(26,563)
Administrative expenses		(7,922)	(7,874)	(7,922)	(7,874)
Other expenses		(340)	(415)	(340)	(415)
Operating profit		24,803	26,934	24,803	26,934
Finance costs		(541)	(116)	(541)	(116)
Share of results of associated companies		(1,565)	(523)	(1,565)	(523)
Profit before tax	A7	22,697	26,295	22,697	26,295
Income tax expense	B6	(5,113)	(5,086)	(5,113)	(5,086)
Net profit for the period		17,584	21,209	17,584	21,209
Other comprehensive income:					
Exchange differences on translation of foreign operations, net of tax		(2)	4,925	(2)	4,925
Total comprehensive income for the period		17,582	26,134	17,582	26,134
Net profit attributable to:					
Equity owners of the parent		17,584	21,209	17,584	21,209
Total comprehensive income attributable to:					
Equity owners of the parent		17,582	26,134	17,582	26,134
Earnings per share attributable to owners of the parent:		Sen	Sen	Sen	Sen
- Basic	B11	2.46	2.97	2.46	2.97
- Diluted	B11	2.46	2.96	2.46	2.96

The Condensed Consolidated Statement of Comprehensive Income should be read in conjunction with the accompanying explanatory notes attached to the Interim Financial Statements.

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2025
(THE FIGURES HAVE NOT BEEN AUDITED)
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2025

	Note	As at 31/3/2025 RM'000	As at 31/12/2024 RM'000 (Audited)
ASSETS			
Non-Current Assets			
Property, plant and equipment	A12	254,492	255,658
Investment properties		9,516	9,070
Intangible assets	A13	9,056	9,144
Right-of-use assets		8,669	9,213
Investments in associated companies		182,321	183,886
Other Investment		994	726
Deferred tax assets		1,093	692
		<u>466,141</u>	<u>468,389</u>
Current Assets			
Inventories		139,214	132,353
Receivables		190,379	192,492
Prepayments		2,585	1,544
Tax recoverable		90	88
Derivative financial instruments	A16 & B12	18	-
Deposits, bank and cash balances		<u>226,634</u>	<u>214,020</u>
		<u>558,920</u>	<u>540,497</u>
TOTAL ASSETS		<u>1,025,061</u>	<u>1,008,886</u>
EQUITY AND LIABILITIES			
Current Liabilities			
Payables		148,262	149,295
Borrowings	B8	7,143	7,143
Lease liabilities		2,167	2,089
Derivative financial instruments	A16 & B12	-	6
Current tax payable		<u>4,960</u>	<u>4,480</u>
		<u>162,532</u>	<u>163,013</u>
Non-Current Liabilities			
Borrowings	B8	38,095	39,881
Lease liabilities		7,122	7,718
Deferred tax liabilities		<u>9,883</u>	<u>8,654</u>
		<u>55,100</u>	<u>56,253</u>
TOTAL LIABILITIES		<u>217,632</u>	<u>219,266</u>
NET ASSETS		<u>807,429</u>	<u>789,620</u>
EQUITY			
Equity attributable to owners of the parent			
Share capital		137,150	137,137
Reserves		18,782	18,570
Retained earnings		<u>651,497</u>	<u>633,913</u>
		<u>807,429</u>	<u>789,620</u>
TOTAL EQUITY		<u>807,429</u>	<u>789,620</u>
		RM	RM
Net Assets per share attributable to owners of the parent		<u>1.13</u>	<u>1.10</u>

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the accompanying explanatory notes attached to the Interim Financial Statements.

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2025
(THE FIGURES HAVE NOT BEEN AUDITED)
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 31 MARCH 2025

Note	← Non-Distributable →		Distributable		
	Share Capital RM'000	Share option reserve RM'000	Foreign currency translation reserve RM'000	Retained Earnings RM'000	Total Equity RM'000
PERIOD ENDED 31 MARCH 2025					
Balance at 1 January 2025	137,137	1,462	17,108	633,913	789,620
Total comprehensive income	-	-	(2)	17,584	17,582
Share options granted	-	216	-	-	216
Transfer to share capital for share options exercised	2	(2)	-	-	-
Transaction with owners					
Dividends on ordinary shares	-	-	-	-	-
Issuance of ordinary share pursuant to ESOS	11	-	-	-	11
Total transaction with owners	11	-	-	-	11
Balance as at 31 March 2025	137,150	1,676	17,106	651,497	807,429
PERIOD ENDED 31 MARCH 2024					
Balance at 1 January 2024	133,287	1,540	20,967	762,480	918,274
Total comprehensive income	-	-	4,925	21,209	26,134
Share options granted	-	176	-	-	176
Share options lapsed	-	(15)	-	15	-
Transfer to share capital for share options exercised	137	(137)	-	-	-
Transaction with owners					
Dividends on ordinary shares	-	-	-	-	-
Issuance of ordinary share pursuant to ESOS	399	-	-	-	399
Total transaction with owners	399	-	-	-	399
Balance as at 31 March 2024	133,823	1,564	25,892	783,704	944,983

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying explanatory notes attached to the Interim Financial Statements.

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2025
(THE FIGURES HAVE NOT BEEN AUDITED)
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE PERIOD ENDED 31 MARCH 2025

	PERIOD ENDED	
	31/3/2025	31/3/2024
	RM'000	RM'000
Operating activities		
Profit before tax	22,697	26,295
Adjustments for:		
Depreciation and amortisation	5,290	4,664
Net profit on disposal of property, plant and equipment	(38)	(127)
Share of results of associated companies	1,565	523
Fair value changes of derivative financial instruments	(24)	14
Share options granted	216	176
Depreciation of right-of-use assets	544	246
Lease interest expense	109	76
Inventories written off/written down net of reversals	89	59
Impairment on receivables net of reversals	(380)	(295)
Interest expense	432	39
Interest income	(1,241)	(2,844)
Operating cash flows before changes in working capital	29,259	28,826
Inventories	(6,950)	(9,644)
Receivables	1,453	(8,995)
Payables	(1,034)	(4,723)
Cash generated from operations	22,728	5,464
Tax paid	(3,807)	(3,231)
Net cash flows generated from operating activities	18,921	2,233
Investing activities		
Investment in trust fund	(268)	-
Purchase of property, plant and equipment & intangible assets	(4,542)	(3,179)
Proceeds from disposal of property, plant and equipment	95	246
(Placement in)/withdrawal from short term deposit	(1)	896
Interest received	1,241	2,844
Net cash flows (used in)/generated from investing activities	(3,475)	807
Financing activities		
Proceeds from issuance of shares under ESOS	11	399
Repayment of term loans	(1,786)	(1,464)
Interest paid	(432)	(39)
Payment of lease liabilities	(626)	(286)
Net cash flows used in financing activities	(2,833)	(1,390)
Net increase in cash and cash equivalents	12,613	1,650
Cash and cash equivalents at 1 January	212,219	380,321
Effect of exchange rate changes on cash and cash equivalents	-	2,296
Cash and cash equivalents at the end of the financial period	224,832	384,267

Included in the deposits, bank and cash balances was RM 1,802,000 (31 March 2024: RM 1,752,000) placed with money market fund held for investment purposes and deposits with licensed banks with tenure more than 3 months. Both of these do not form part of cash and cash equivalents.

The Condensed Consolidated Statement of Cash Flow should be read in conjunction with the accompanying explanatory notes attached to the Interim Financial Statements.

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2025
(THE FIGURES HAVE NOT BEEN AUDITED)
A NOTES PURSUANT TO MFRS 134 FOR THE PERIOD ENDED 31 MARCH 2025
A1 Basis of preparation

These unaudited condensed consolidated interim financial statements for the period ended 31 March 2025 have been prepared in accordance with MFRS 134 Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad. These unaudited condensed consolidated interim financial statements also comply with IAS 34 Interim Financial Reporting issued by the International Accounting Standards Board. It should be read in conjunction with the Group's most recent audited financial statements for the year ended 31 December 2024.

These unaudited condensed consolidated interim financial statements have been prepared on a historical cost basis except for certain financial assets and liabilities classified as financial assets and liabilities at fair value through profit or loss, other comprehensive income and financial assets designated as available for sale.

A2 Significant accounting policies

The significant accounting policies adopted in preparing these unaudited condensed consolidated interim financial statements are consistent with those of the audited financial statements for the year ended 31 December 2024 except for the adoption of the following standards, wherever applicable to the Group and Company:

Description	Effective for annual periods beginning on or after
Amendments to MFRS 121: Lack of Exchangeability	1 January 2025
Annual Improvements to MFRS Accounting Standards - Volume 11	1 January 2026
Amendments to MFRS 7 and MFRS 9: Classification and Measurement of Financial Instruments	1 January 2026
Amendments to MFRS 7 and MFRS 9: Contracts Referencing Nature-dependent Electricity	1 January 2026
MFRS 18: Presentation and Disclosure in Financial Statements	1 January 2027
MFRS 19: Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to MFRS 10 and MFRS 128: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	Deferred

The initial application of the abovementioned standards and amendments do not have any material impacts to the current and prior periods financial statements upon their first adoption.

A3 Seasonality or cyclicity of interim operations

The Group's interim operations are not affected materially by any seasonal or cyclical factors.

A4 Unusual items

There were no unusual items that affected the assets, liabilities, equity, net income or cash flows for the period ended 31 March 2025.

A5 Changes in estimates of amounts reported in prior interim periods of the current financial year or in prior financial year

There were no changes in estimates of amounts reported in the prior interim periods of the current financial year or in prior financial year.

A6 Issuances, cancellations, repurchases, resale and repayments of debt and equity securities

There were no issuance and/or repayment of debt and equity securities, share buy-backs, share cancellations, shares held as treasury shares and resale of treasury shares during the first quarter ended 31 March 2025 except for the issuance of 9,000 new ordinary shares pursuant to the exercise of options under the Executive Share Options Scheme ("ESOS").

A7 Profit before tax

Included in profit before tax are the following items:

	3 MONTHS ENDED		PERIOD ENDED	
	31/3/2025	31/3/2024	31/3/2025	31/3/2024
	RM'000	RM'000	RM'000	RM'000
Interest income	1,241	2,844	1,241	2,844
Other income including investment income	1,624	1,978	1,624	1,978
Interest expense	(432)	(39)	(432)	(39)
Depreciation and amortisation	(5,290)	(4,664)	(5,290)	(4,664)
Depreciation of right-of-use assets	(544)	(246)	(544)	(246)
Impairment on receivables net of reversals	380	295	380	295
Inventories written off/written down net of reversals	(89)	(59)	(89)	(59)
Net profit on disposal of property, plant and equipment	38	127	38	127
Fair value changes of derivative financial instruments	24	(14)	24	(14)
Foreign exchange gain	55	947	55	947

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2025
(THE FIGURES HAVE NOT BEEN AUDITED)
A NOTES PURSUANT TO MFRS 134 FOR THE PERIOD ENDED 31 MARCH 2025 (continued)
A8 Dividends paid and declared

There were no dividends paid during the current period ended 31 March 2025.

A9 Segment Information

The Group is organised into three main business units based on their activities, and has three reportable operating segments as follows:

- (i) Manufacturing of pharmaceutical products ("Manufacturing");
- (ii) Distribution of pharmaceutical and healthcare products ("Distribution"); and
- (iii) Corporate comprising investments, properties and others ("Corporate").

OPERATING SEGMENTS
PERIOD ENDED 31/3/2025

	Manufacturing RM'000	Distribution RM'000	Corporate RM'000	Adjustments RM'000	GROUP RM'000
External Revenue	19,321	219,428	121	-	238,870
Inter-segment revenue	43,831	3	1,619	(45,453)	-
Total Revenue	63,152	219,431	1,740	(45,453)	238,870
Segment Results	16,903	7,940	(852)	(753)	23,238
Finance costs					(541)
Profit before tax					22,697

PERIOD ENDED 31/3/2024

External Revenue	25,783	222,353	42	-	248,178
Inter-segment revenue	45,053	37	1,541	(46,631)	-
Total Revenue	70,836	222,390	1,583	(46,631)	248,178
Segment Results	19,984	8,210	(106)	(1,677)	26,411
Finance costs					(116)
Profit before tax					26,295

Segment assets

31-Mar-2025	333,660	370,248	329,123	(7,970)	1,025,061
31-Dec-2024	322,228	367,078	327,997	(8,417)	1,008,886

Segment liabilities

31-Mar-2025	(78,319)	(121,965)	(2,505)	(14,843)	(217,632)
31-Dec-2024	(79,508)	(120,785)	(5,839)	(13,134)	(219,266)

A10 Significant Events After the Reporting Date

There were no significant events that had arisen subsequent to the end of this current period.

A11 Changes in Group Composition

The Group did not undertake any business combinations, acquisitions or disposals of subsidiaries and long-term investments, restructuring or discontinuation of operations during the current quarter ended 31 March 2025.

A12 Property, plant and equipment

During the current quarter ended 31 March 2025, the capital expenditure paid by the Group was RM 4.4 million (31 March 2024: RM 0.5 million).

Asset with carrying amount of RM 57,000 was disposed by the Group during the current quarter ended 31 March 2025 (31 March 2024: RM 119,000) and resulting in a net disposal gain of RM 38,000 (31 March 2024: RM 127,000).

There was no material asset written off in the current quarter and the corresponding quarter in the previous year.

A13 Intangible assets

There was no intangible asset written off in the current quarter and the corresponding quarter in the previous year.

A14 Capital Commitments

Capital commitments of property, plant and equipment not provided for in the financial statements as at 31 March 2025 are as follows:

	RM'000
Authorised capital expenditure approved and contracted for	3,719
Authorised capital expenditure approved but not contracted for	24,515
	28,234

A NOTES PURSUANT TO MFRS 134 FOR THE PERIOD ENDED 31 MARCH 2025 (continued)

A15 Related Party Transactions

The Group did not have any significant transactions with related parties during the period ended 31 March 2025 in addition to the related party transactions disclosed in the audited financial statements for the year ended 31 December 2024.

A16 Fair value hierarchy

The Group uses the following level of fair value hierarchy for determining the fair value of its financial instruments carried at fair value.

Financial assets/(liabilities):	31/3/2025 RM'000	31/12/2024 RM'000
	(Level 2)	
Other investment	994	726
Derivatives - Forward currency contracts	18	(6)

The Group classifies fair value measurement using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and

Level 3 – Inputs for the asset or liability that are not based on observable market data (unobservable inputs).

There have been no transfers between the fair value hierarchy during the current interim period and financial year ended 2025 and 2024.

A17 Changes in Contingent liabilities or Contingent assets

There were no contingent liabilities or contingent assets of the Group since the end of the last annual reporting date.

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2025

(THE FIGURES HAVE NOT BEEN AUDITED)

B NOTES PURSUANT TO BURSA LISTING REQUIREMENTS: CHAPTER 9, APPENDIX 9B, PART A
B1 Detailed Performance Analysis of Operating Segments of the Group

	Individual Period		Changes	Cumulative Period		Changes
	Current Year Quarter	Preceding Year Corresponding Quarter		Current Year To-date	Preceding Year To-date	
	31/3/2025	31/3/2024		31/3/2025	31/3/2024	
	RM'000	RM'000		RM'000	RM'000	
Revenue	238,870	248,178	(3.8%)	238,870	248,178	(3.8%)
EBITDA (excluding share of results of associated companies)	29,397	28,999	1.4%	29,397	28,999	1.4%
Operating Profit	24,803	26,934	(7.9%)	24,803	26,934	(7.9%)
Share of results of associated companies	(1,565)	(523)	199.2%	(1,565)	(523)	199.2%
Finance Cost	(541)	(116)	366.4%	(541)	(116)	366.4%
Profit Before Tax	22,697	26,295	(13.7%)	22,697	26,295	(13.7%)
Profit After Tax	17,584	21,209	(17.1%)	17,584	21,209	(17.1%)

Review of Current Quarter Performance versus Corresponding Quarter Last Year

In Q1 2025, the Group's achieved consolidated revenue of RM 238.9 million, higher than the RM 237.5 million in the preceding quarter and 3.8% lower than the RM 248.2 million reported in the same period last year. Revenue growth was tempered by lower Malaysian public sector sales due to the timing and mix of tender contracts secured. Revenue from this sector is expected to resume its growth trajectory in the second quarter. Notably, Group revenue in Q1 2024 is the historic high, partly boosted by non-recurring Singapore public sector purchases to bolster inventories.

Operating expenses were well controlled and in line with revenue. Other income declined 49.0% compared to Q1 2024, which was helped by higher interest income from holding cash dividends received from 40% associate Straits Apex Group Sdn Bhd ('SAG') as well as forex gain.

Earnings before Interest, Taxation, Depreciation and Amortization ('EBITDA') and associates reached RM 29.4 million for the quarter, 1.4% higher than RM 29.0 million reported for the same period in 2024. Operating profit for the first quarter is RM 24.8 million, 7.9% lower than the RM 26.9 million recorded in Q1 2024, due largely to the impact of depreciation and amortization charges from Cheng 2 and Techlink, both of which were assets acquired in the second half of 2024 to support longer-term business growth.

In the current quarter, the Group recognised a share of loss amounting to RM 1.6 million from its 40%-owned associate, SAG, compared to a share of loss of RM 0.5 million recorded in the first quarter of 2024. The higher loss was primarily attributable to the slower-than-anticipated recovery in customer orders, as well as SAG's continued recognition of amortisation and financing costs associated with its divestment of a 60% equity interest in Straits Apex Sdn Bhd ('SA') in May 2023 (the 'Straits Divestment').

Impacted by a higher share of loss from SAG, lower other Income and higher depreciation expense from Cheng 2 and Techlink, Group profit before tax for the first quarter is RM 22.7 million, 13.7% lower than the RM 26.3 million achieved in the corresponding period in 2024.

During the quarter, Xepa-Soul Pattinson (M) Sdn Bhd ('Xepa') obtained GMP Clearance from the Australian Therapeutic Goods Administration ('TGA') for the Sterile Finished Product category, complementing the Non-Sterile Finished Product clearance received in 2020. Xepa also commenced operations at its new pharmaceutical warehouse at Cheng 2 on 25 March 2025, having obtained all necessary approvals and licenses. This has enabled Xepa to consolidate warehousing operations more efficiently by reducing the use of external third party warehouses. 6 new Group branded products were brought to the market in the first quarter by Xepa and ABio Marketing Sdn Bhd ('ABio'), comprising an equal number of pharmaceutical and consumer healthcare products.

B2 Material Changes in the Profit Before Tax for the Quarter

	Current Quarter 31/3/2025	Immediate Preceding Quarter 31/12/2024	Changes	
	RM'000	RM'000	RM'000	(%)
Revenue	238,870	237,501	1,369	0.6%
EBITDA (excluding share of results of associated companies)	29,397	33,771	(4,374)	(13.0%)
Operating Profit	24,803	29,196	(4,393)	(15.0%)
Share of results of associated companies	(1,565)	(6,588)	(5,023)	(76.2%)
Finance Cost	(541)	(505)	36	7.1%
Profit Before Tax	22,697	22,103	594	2.7%
Profit After Tax	17,584	13,461	4,123	30.6%

There is no material change in Profit before Taxation for the first quarter of 2025 when compared to the preceding quarter.

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2025
(THE FIGURES HAVE NOT BEEN AUDITED)
B NOTES PURSUANT TO BURSA LISTING REQUIREMENTS: CHAPTER 9, APPENDIX 9B, PART A (continued)
B3 Commentary
a Prospects

The recent imposition of global tariffs by the United States presents a challenge to Malaysia's economic outlook, necessitating a reassessment of the nation's projected Gross Domestic Product ('GDP') growth rate, previously estimated at 4.5% to 5.5% for 2025. Structural shifts in the global trading order are expected to weigh on economic activity, fueling concerns about a potential recession and dampening consumer confidence. In response to evolving macroeconomic conditions, Singapore has revised its 2025 GDP growth forecast downward to a range of 0% to 2%.

The Group's core pharmaceutical business does not involve exports to the United States of America ('US'), and, as such, the newly announced tariffs are not anticipated to have a material direct impact on its operations. However, its 40%-owned associate, Straits Apex Group Sdn Bhd ('SAG'), has affiliates engaged in the manufacturing and export of orthopaedic devices, with a predominant focus on the US market. While SAG does not foresee any immediate significant effects, its associates remain proactively engaged in strategic discussions with key US customers to explore longer-term mitigation strategies.

During an economic downturn, generic pharmaceutical companies stand to benefit as cost-conscious consumers and healthcare providers prioritize affordability without compromising quality. With reduced disposable income, patients increasingly opt for generic alternatives, which offer the same efficacy as branded drugs at significantly lower prices. Governments and insurers also favor generics as a means to curb healthcare costs, driving stronger demand and expanding the market share of generic manufacturers. The Group, therefore, expects healthcare spending to remain resilient in 2025.

In alignment with its strategic priorities, the Group remains committed to proactively managing risks, strengthening its operational fundamentals, and maintaining agility to capitalize on new growth opportunities as they arise. Supported by a robust balance sheet and a strong net cash position, the Group is well-equipped to swiftly navigate evolving market conditions and leverage emerging prospects. Guided by its long-term vision, the Group remains confident in its ability to deliver sustainable growth and create enduring value for stakeholders.

b Progress to achieve forecast revenue or profit estimate

Not applicable.

B4 Statement by the Board of Directors' opinion on the achievability of forecast revenue or profit estimate

Not applicable.

B5 Profit Forecast / Profit Guarantee

Not applicable.

B6 Income Tax Expense

In respect of current period:

Income tax
Deferred tax
Foreign tax

3 MONTHS ENDED		PERIOD ENDED	
31/3/2025	31/3/2024	31/3/2025	31/3/2024
RM'000	RM'000	RM'000	RM'000
4,138	4,864	4,138	4,864
827	(399)	827	(399)
148	621	148	621
5,113	5,086	5,113	5,086

The effective tax rate (excluding the share of results of associated companies) for current quarter increased from previous year corresponding quarter due to the expiry of Reinvestment Allowance and provision for deferred tax arising from the recognition of right-of-use assets.

B7 Status of Corporate Proposals

There were no corporate proposals announced but not completed as at 13 May 2025.

B8 Group Borrowings and Debt Securities

	As at 31/3/2025		
	Long Term	Short Term	Total Borrowings
	RM'000	RM'000	RM'000
Secured			
Secured bank loans	38,095	7,143	45,238
	As at 31/12/2024		
	Long Term	Short Term	Total Borrowings
	RM'000	RM'000	RM'000
Secured			
Secured bank loans	39,881	7,143	47,024

INTERIM FINANCIAL STATEMENTS FOR THE FIRST QUARTER ENDED 31 MARCH 2025
(THE FIGURES HAVE NOT BEEN AUDITED)
B NOTES PURSUANT TO BURSA LISTING REQUIREMENTS: CHAPTER 9, APPENDIX 9B, PART A (continued)
B8 Group Borrowings and Debt Securities (continued)

The bank borrowings is to part finance the acquisition of Cheng 2 by Xepa-Soul Pattinson (M) Sdn Bhd, a wholly-owned subsidiary of the Company. The loan is denominated in Ringgit Malaysia and secured by a Corporate Guarantee provided by the Company. The interest rates are tagged to a percentage margin above one-month KLIBOR. Other than the principal repayments, there were no material changes in the amount of borrowings at the end of the current quarter compared to the end of the previous financial year ended 31 December 2024.

B9 Material Litigation

There was no pending material litigation at the date of this report.

B10 Dividend Payable

The Board of Directors does not recommend the payment of any interim dividend for the period ended 31 March 2025 (31 March 2024: Nil).

B11 Earnings per share

The following reflect the profit and share data used in the computation of basic and diluted earnings per share:

		3 MONTHS ENDED		PERIOD ENDED	
		31/3/2025	31/3/2024	31/3/2025	31/3/2024
<u>Basic Earnings per share</u>					
Profit after tax	RM'000	17,584	21,209	17,584	21,209
Weighted average number of ordinary shares in issue	'000	715,312	714,546	715,312	714,546
Basic earnings per share	sen	2.46	2.97	2.46	2.97
<u>Diluted Earnings per share</u>					
Profit after tax	RM'000	17,584	21,209	17,584	21,209
Weighted average number of ordinary shares in issue	'000	715,312	714,546	715,312	714,546
Effect of dilution-Share options	'000	27	820	27	820
Adjusted weighted average number of ordinary shares in issue	'000	715,339	715,366	715,339	715,366
Diluted earnings per share	sen	2.46	2.96	2.46	2.96

B12 Derivative Financial Instruments

The Group is exposed to foreign currency exchange risk as a result of foreign currency transactions entered into currencies other than their functional currencies by the subsidiary companies. These companies enter into short-term forward foreign exchange contracts to manage their exposure to fluctuations in foreign currency exchange rates on specific transactions arising from trade receivables and payables.

Type of Derivatives	Contract/ Notional Value	Fair Value
	31/3/2025 RM'000	31/3/2025 RM'000
i) Forward Foreign Currency Contract entered into for the purchase of goods from foreign contract manufacturers or suppliers - Less than 1 year	(1,807)	(1,789)
	(1,807)	(1,789)

No derivative was entered into by the Company which has not been disclosed in the preceding financial year or any quarters in the current financial year. Since the end of the previous financial year or any quarters in the current financial year, there was no change in any of the information disclosed in respect of the following:

- The credit risk, market risk and liquidity risks associated with the derivatives;
- The policies in place for mitigating or controlling the risks associated with these derivatives;
- The related accounting policies.

The net cash requirements relating to these contracts was RM 1,807,000.

B NOTES PURSUANT TO BURSA LISTING REQUIREMENTS: CHAPTER 9, APPENDIX 9B, PART A (continued)

B13 Fair Value Changes of Financial Assets

As at 31 March 2025, the Group did not have any significant financial assets measured at fair value through profit or loss and other comprehensive income other than the disclosure in note A16.

B14 Auditors' report on preceding annual financial statements

The Auditors' report on the Group's financial statements for the year ended 31 December 2024 was not qualified.

Authorisation for issue

The interim financial statements have been approved for issue in accordance with a resolution of the Board of Directors dated 21 May 2025.